GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (XMAD:PHM) » Definitions » E10

Pharma Mar (XMAD:PHM) E10 : €1.53 (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Pharma Mar E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Pharma Mar's adjusted earnings per share data for the three months ended in Dec. 2024 was €1.063. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €1.53 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Pharma Mar's average E10 Growth Rate was 7.00% per year. During the past 3 years, the average E10 Growth Rate was 10.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Pharma Mar was 78.90% per year. The lowest was 10.30% per year. And the median was 35.90% per year.

As of today (2025-03-17), Pharma Mar's current stock price is €89.75. Pharma Mar's E10 for the quarter that ended in Dec. 2024 was €1.53. Pharma Mar's Shiller PE Ratio of today is 58.66.

During the past 13 years, the highest Shiller PE Ratio of Pharma Mar was 541.41. The lowest was 19.44. And the median was 50.46.


Pharma Mar E10 Historical Data

The historical data trend for Pharma Mar's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar E10 Chart

Pharma Mar Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 1.14 1.45 1.43 1.53

Pharma Mar Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.43 1.35 1.37 1.38 1.53

Competitive Comparison of Pharma Mar's E10

For the Biotechnology subindustry, Pharma Mar's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Shiller PE Ratio falls into.



Pharma Mar E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharma Mar's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=1.063/124.7533*124.7533
=1.063

Current CPI (Dec. 2024) = 124.7533.

Pharma Mar Quarterly Data

per share eps CPI Adj_EPS
201503 0.358 99.474 0.449
201506 -0.176 101.138 -0.217
201509 0.239 99.559 0.299
201512 -0.060 100.268 -0.075
201603 -0.387 98.638 -0.489
201606 -0.328 100.333 -0.408
201609 -0.185 99.737 -0.231
201612 -0.407 101.842 -0.499
201703 -0.134 100.896 -0.166
201706 -0.271 101.848 -0.332
201709 -0.381 101.524 -0.468
201712 -0.666 102.975 -0.807
201803 -0.071 102.122 -0.087
201806 0.237 104.165 0.284
201809 -0.226 103.818 -0.272
201812 -0.240 104.193 -0.287
201903 -0.568 103.488 -0.685
201906 -0.588 104.612 -0.701
201909 -0.306 103.905 -0.367
201912 0.843 105.015 1.001
202003 3.815 103.469 4.600
202006 2.353 104.254 2.816
202009 0.952 103.521 1.147
202012 0.341 104.456 0.407
202103 1.332 104.857 1.585
202106 1.048 107.102 1.221
202109 0.633 107.669 0.733
202112 2.119 111.298 2.375
202203 1.220 115.153 1.322
202206 0.716 118.044 0.757
202209 0.467 117.221 0.497
202212 0.331 117.650 0.351
202303 0.079 118.948 0.083
202306 0.279 120.278 0.289
202309 0.085 121.343 0.087
202312 -0.387 121.300 -0.398
202403 0.131 122.762 0.133
202406 0.071 124.409 0.071
202409 0.225 123.121 0.228
202412 1.063 124.753 1.063

Add all the adjusted EPS together and divide 10 will get our e10.


Pharma Mar  (XMAD:PHM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Pharma Mar's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=89.75/1.53
=58.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Pharma Mar was 541.41. The lowest was 19.44. And the median was 50.46.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Pharma Mar E10 Related Terms

Thank you for viewing the detailed overview of Pharma Mar's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Mar Business Description

Traded in Other Exchanges
Address
Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.